Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer (NCT00999843) | Clinical Trial Compass
UnknownPhase 1/2
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
China30 participantsStarted 2009-10
Plain-language summary
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy. Hypothesis of the current study is that Sorafenib as a maintenance therapy is safe and superior to radiotherapy combined with interventional therapy in terms of survival in comparison to historical data.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age of equal or older than 18 years and not over 75 years with a life expectancy of at least 12 weeks;
✓. Karnofsky performance status (KPS) of ≥70;
✓. Histologically or cytologically confirmed HCC;
✓. BCLC stage B, solitary lesion (bigger than 5 cm in diameter) with tumor burden less than 50% of total liver volume;
✓. Liver function of Child-Pugh A;
✓. Technically unresectable, medically inoperable, or surgery declined by the patient;
✓. Normal renal function and adequate bone marrow reservation;
✓. Signed informed consent must be obtained prior to any study specific procedure.
Exclusion criteria
✕. Presence of intrahepatic and/or extrahepatic metastases
✕. Previous received systemic therapy for liver cancer;
✕. History of radiotherapy to the liver;
✕. Indistinct tumor boundary on CT/MRI images;
✕. Previous or concurrent malignancies, with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder tumors \[Ta, Tis and T1\];
What they're measuring
1
The safety and tolerability of maintenance Sorafenib.
✕. History of cardiac disease: congestive heart failure \> NYHA class 2, active CAD, cardiac arrythmias requiring anti-arrhythmic therapy or uncontrolled hypertension within the last 12 months;